Lynn Cilinski - 08 Feb 2024 Form 4 Insider Report for MACROGENICS INC (MGNX)

Reporting relationship: VP, Controller and Treasurer
Issuer ticker: MGNX
Reported as of: 08 Feb 2024
Net transaction value: +$823,500
SEC form: 4
Accepted by SEC: 12 Feb 2024, 17:32:59 UTC
Prior SEC filing: 17 Feb 2023
Next SEC filing: 20 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Lynn M. Cilinski, Attorney-in-fact

Key filing fact

Lynn Cilinski filed Form 4 for MACROGENICS INC (MGNX) on 12 Feb 2024.

Key facts

This page summarizes Lynn Cilinski's Form 4 filing for MACROGENICS INC (MGNX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Feb 2024, 17:32.

Change

Previous filing in this sequence was filed on 17 Feb 2023.
Current net transaction value: +$823,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MGNX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $823,500
Shares: +45,000
Change %
Price: $18.30
Shares after: 45,000
Date: 08 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 45,000
Exercise price: $18.30
Footnotes: F1

MGNX transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +17,000
Change %
Price: $0.000000
Shares after: 17,000
Date: 08 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,000
Exercise price: $0.000000
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.

Footnote F2

Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

Footnote F3

The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.